THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014
AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
07 May
2024
Graft Polymer (UK)
Plc
(the
"Company")
Grant of Haemostatic Hydrogel
Patent
Following the publication of the
Company's audited accounts for the year ended 31 December 2023 on
30 April 2024, which included an accounting impairment of the
Company's plastic manufacturing plant in Slovenia, the Company
announced the disposal of Graft Polymer d.o.o., its wholly owned
Slovenian subsidiary, on 3 May 2024.
This disposal enables the Company to
focus its attention and resources on its Graft Bio division, which
represents, in the Directors' opinion, strong prospectivity
through its intellectual property (IP), licensing agreements, and
sales contracts.
The Company is pleased to announce
the grant of patent P-202400066, titled "Dual hydrogel
multi-crosslinking haemostatic composition and method of
manufacturing thereof", to further strengthen the Company's IP
portfolio.
The disclosed dual hydrogel
multi-crosslinking haemostatic composition offers a groundbreaking
solution for emergency haemostasis by amalgamating two distinct
gels, each possessing unique cross-linking mechanisms and bioactive
components. Gel A, containing sodium carboxymethylcellulose
(Na-CMC) and tranexamic acid (TXA), is ionically cross-linked with
calcium ions (Ca+), while Gel B, comprising cationic carboxymethyl
chitosan (CMCS) and sodium alginate (Na-Alginate), undergoes
electrostatic and ionic cross-linking with boron ions
(B-).
Stored separately but applied
together using a dual-chamber syringe, these gels intermix at the
bleeding site, facilitating immediate formation of a final hydrogel
with enhanced mechanical properties and adhesive
strength.
This composition fulfils the
imperative for effective, user-friendly haemostatic agents in
emergency settings, offering biocompatibility, antibacterial
properties, and pro-healing effects, thereby presenting a versatile
solution for various surgical procedures, trauma care, and
veterinary medicine, while also serving as a potential scaffold for
tissue engineering or drug delivery.
Anthony Tennyson, CEO, commented:
"The global emergency hemostasis products market is
significant and growing, and the grant of this patent underscores
the potential of our Graft Bio division. With our enhanced
hemostasis IP portfolio, we are well-equipped to address the
evolving needs of healthcare professionals and patients in this
segment. Concurrently, we are actively pursuing our previously
announced review of the Company's operations to identify additional
opportunities for growth."
Enquiries:
Graft Polymer
(UK) Plc
Anthony Tennyson, CEO and Executive Director,
anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director
Allenby
Capital (Broker)
Nick Naylor / Liz Kirchner (Corporate
Finance)
Guy McDougall (Sales)
+44 (0) 20 3328 5656
